Julian Baker
CIK 1087939 · last filed 2026-09-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$625.23M
Companies
39
Total Filings
405
Lifetime Open-Market Net
$3.31B
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INCY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestOfficerDirector10% owner* stale (no filing in 3 yrs)
Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Reported Address
BAKER BROS. ADVISORS LP860 WASHINGTON STREET 3RD FLOOR
NEW YORK, NY 10014
Related Filers
Felix Baker — 1,524 joint filings, latest 2026-09-30
BAKER BROS. ADVISORS LP — 591 joint filings, latest 2026-08-11
Baker Bros. Advisors (GP) LLC — 559 joint filings, latest 2026-09-30
Baker Brothers Life Sciences LP — 525 joint filings, latest 2026-08-11
667, L.P. — 520 joint filings, latest 2026-08-11
INCYTE CORP — 250 joint filings, latest 2026-07-02
Baker Brothers Life Sciences Capital (GP), LLC — 244 joint filings, latest 2012-03-14
14159 capital (GP), LLC — 216 joint filings, latest 2012-03-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KOD | Director | 1,611,909 | $89.60 | $144.43M | $777.82M | 5 | 2026-09-30 |
| REPL | Director | — | $12.47 | — | $0 | 1 | 2026-08-11 |
| INCY | Director | 314,600 | $113.31 | $35.65M | $1.09B | 79 | 2026-07-02 |
| ONC | Director | 161,551 | $370.87 | $59.91M | $0 | 1 | 2026-06-15 |
| PRLD | Director | — | $3.70 | — | $0 | 3 | 2026-06-10 |
| TRDA | 10%+ Owner | 381,338 | $4.75 | $1.81M | $1.05M | 2 | 2025-11-24 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 357,048 | $1.27 | $453.5K | $20.55M | 8 | 2025-07-02 |
| KYMR | Director | — | $114.84 | — | $0 | 1 | 2025-06-26 |
| KNSA | Director | 2,753,656 | $72.98 | $200.96M | $0 | 3 | 2025-06-05 |
| DNLI | Director | 3,415,958 | $18.66 | $63.74M | $0 | 1 | 2025-06-05 |
| BCYC | Director | 918,483 | $3.65 | $3.35M | $0 | 2 | 2025-01-06 |
| KALA | 10%+ Owner | 2,370 | $0.19 | $441 | $8.00M | 1 | 2024-12-31 |
| Talis Biomedical Corp (TLIS) Delisted | Director | — | $2.84 | — | $0 | 1 | 2022-06-13 |
| ACAD | Director | 3,609,489 | $19.74 | $71.25M | $0 | 8 | 2022-06-09 |
| TCRX | Director | — | $0.19 | — | $0 | 1 | 2022-06-03 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 2 | 2022-05-16 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2021-02-25 |
| Atreca, Inc. (BCEL) Delisted | 10%+ Owner | 309,730 | $0.15 | $46.5K | $0 | 2 | 2020-07-20 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 5,293,600 | $184.71 | $977.78M | $321.33M | 4 | 2020-06-19 |
| Seagen Inc. (SGEN) Delisted | Director | 46,041,889 | $228.74 | $10.53B | $1.10B | 32 | 2020-04-24 |
| ZYME | Director | — | $28.37 | — | $0 | 1 | 2020-03-16 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 1,216,909 | — | — | -$101.91M | 69 | 2019-08-30 |
| Aceragen, Inc. (IDRA) Delisted | Director | 1,290 | $7.22 | $9.3K | -$13.97M | 22 | 2019-06-07 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | 10%+ Owner | 5,813 | $0.07 | $435 | -$28.88M | 1 | 2018-01-19 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | — | $58.70 | — | $0 | 1 | 2017-11-20 | |
| Invitae Corp (NVTA) Delisted | 10%+ Owner | — | $0.09 | — | $0 | 1 | 2017-08-02 |
| NTLA | 796,683 | $11.26 | $8.97M | $14.40M | 1 | 2016-05-11 | |
| Neurogene Inc. (AQXP) Delisted | 10%+ Owner | 826,628 | — | — | $27.87M | 3 | 2016-03-16 |
| XOMA Royalty Corp (XOMA) Delisted | Director | 741,631 | $40.17 | $29.79M | $33.63M | 4 | 2014-12-30 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 295,001 | — | — | $10.19M | 2 | 2012-03-14 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 1,736,065 | — | — | $0 | 4 | 2012-01-09 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 303,264 | — | — | -$6.20M | 24 | 2011-12-16 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 126,709 | — | — | $52.46M | 11 | 2011-07-05 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 6,992 | — | — | $81.52M | 5 | 2011-03-31 |
| RPRX | 10%+ Owner | 44,970 | $64.76 | $2.91M | $1.22M | 4 | 2010-06-02 |
| NEUROGEN CORP (NRGN) Delisted | Director | 3,500,059 | — | — | $0 | 18 | 2009-12-17 |
| BCRX | 10%+ Owner | 4,090,786 | $7.88 | $32.24M | -$9.19M | 4 | 2009-06-01 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 2,022,293 | — | — | -$69.50M | 26 | 2009-02-06 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 550,546 | — | — | -$9.23M | 11 | 2007-11-15 |
Recent Filings · Page 3 of 41
405 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-03-15 | INCY | Exer (M) | +240,000 | $5.46M | EDGAR |
| 2022-06-13 | Talis Biomedical Corp (TLIS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | ACAD | Grant (A) | +205,248 | $0 | EDGAR |
| 2022-06-06 | KOD | Buy (P) | +3,434,094 | $26.69M | EDGAR |
| 2022-06-03 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2022-05-16 | Neurogene Inc. (NLTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-04-04 | INCY | Grant (A) | +5,280 | $0 | EDGAR |
| 2022-03-10 | INCY | Mixed | +2,574,480 | $173.94M | EDGAR |
| 2022-02-22 | INCY | Buy (P) | +3,154,824 | $214.41M | EDGAR |
| 2022-02-14 | INCY | Buy (P) | +9,590,244 | $641.71M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.